Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/145—Orthomyxoviridae, e.g. influenza virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5254—Virus avirulent or attenuated
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5256—Virus expressing foreign proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/16011—Orthomyxoviridae
  • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
  • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/16011—Orthomyxoviridae
  • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
  • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/16011—Orthomyxoviridae
  • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
  • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
  • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/16011—Orthomyxoviridae
  • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
  • C12N2760/16161—Methods of inactivation or attenuation
  • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2840/00—Vectors comprising a special translation-regulating system
  • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2840/00—Vectors comprising a special translation-regulating system
  • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Definitions

• the invention relates to recombinant influenza viruses for high-yield expression of incorporated foreign gene(s), which are genetically stable in the absence of any helper virus and which comprise at least one viral RNA segment being a tandem bicistronic RNA molecule coding for two genes in tandem, in said tandem bicistronic RNA molecule one of the standard viral genes being in covalent junction with a foreign, recombinant gene and having an upstream splice donor and a downstream splice acceptor signal surrounding the proximal coding region.
• tandem bicistronic RNA molecule contains one of the standard viral genes in distal mRNA position behind a foreign, recombinant gene in proximal position, or vice versa, both in antisense orientation with regard to the viral RNA within the virus.
• the proximal reading frame is flanked by splice donor and acceptor signals which have the quality to allow a partial yield of spliced mRNA only, i.e., resulting in the presence of both, spliced and unspliced mRNA simultaneously.
• the invention further provides a method for obtaining attenuated viruses which resist reassortment dependent progeny production in case of chance superinfections by wild-type influenza viruses; a method for the production of said recombinant influenza viruses; pharmaceutical compositions comprising said recombinant influenza viruses; and the use of said recombinant influenza viruses . for preparing medicaments for vaccination purposes.
• Redesigning influenza virus into a vector system for expression of foreign genes similar to what has been achieved in several other thoroughly studied viruses such as adenovirus, retrovirus, Semliki Forest virus or Rabies virus has the advantage of an industrially well established mode of cheap propagation for influenza in fertilized chicken eggs leading to rather high titers (above 10 10 /ml).
• adenovirus, retrovirus, Semliki Forest virus or Rabies virus has the advantage of an industrially well established mode of cheap propagation for influenza in fertilized chicken eggs leading to rather high titers (above 10 10 /ml).
• none of the constituent vRNA segments may be deleted from the influenza genome according to our present knowledge, and give room for large-size foreign insertions. Only small fragments of foreign polypeptide chains such as B cell epitopes (10 to 15 amino acids) may be inserted into selected positions within two of the viral proteins, i.e.
• promoter-up mutations modified terminal viral RNA sequences (hereinafter "promoter-up mutations" or promoter-up variants”) have been designed by nucleotide substitutions (Neumann and Hobom, Mutational analysis of influenza virus promoter elements in vivo, J.
• promoter-up variants carry up to five nucleotide substitutions (in promoter-up variant 1920; see Flick and Hobom, J. Gen. Virol. 80, 2565- 2572 (1999)).
• promoter-up variants When these promoter-up variants are attached to a recombinant ninth vRNA segment its increased transcription and amplification rate will not only compensate for the losses suffered spontaneously, but even cause accumulation of the foreign vRNA segment during simple viral passaging, in the absence of any selection.
• a balanced situation with regard to the insert length and the level of promoter activity can be achieved, and has been propagated in a particular case over 11 passages, with essentially stable levels of recombinant viruses among a majority of helper viruses (around 80%) during these steps. If a full-level promoter-up mutation is used (1104 or the variant 1920, see below) a balanced-level propagation is reached in conjunction with a recombinant vRNA size of 4000 nucleotides (Maysa Azzeh, Ph.D. Thesis, Univ. Giessen (2000)).
• a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus and which comprises at least one viral RNA segment being an ambisense RNA molecule (designated "ambisense RNA segment") and containing one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation, or w ' ce versa, in overall convergent arrangement (PCT/EPOO/01903).
• the ambisense RNA segment preferably should contain the promoter-up mutations.
• the PCT/EPOO/01903 moreover discloses a method of constructing specific influenza carrier (helper) strains carrying one or more ribozyme target sites (of type one) in vRNA flanking positions comprising
• RNA polymerase I synthesis of recombinant vRNAs in vivo, carrying two different 3 1 promoter sequences in tandem (an external promoter-up variant and an internal wild-type promoter), which are separated by a second type of ribozyme target sequence, and which carry the said internal ribozyme target sites of type one;
• the resulting special helper virus strains carrying a vRNA segment with external ribozyme target sites of type 1 in exchange for the equivalent regular vRNA molecule are then used for the rescue of ambisense RNA molecules. These are exclusively maintained in the recombinant viruses after passage of viral propagation through ribozyme (type 1) containing host cells, which will destroy the sensitive vRNA molecules of the specially prepared helper viruses.
• the above ambisense constructs are susceptible to (intranuclear) mRNA double-strand formation, which will partially reduce the expression rates of both the ambisense genes, in particular the gene driven by the (weaker) cRNA promoter.
• the fluctuating extent of this effect made it difficult to bring the expression rate of the influenza gene within the ambisense segment into balance with other influenza genes. This was the problem to be solved with the present invention.
• the recombinant viruses of the present invention can be used for cheap propagation in fertilized eggs, either for production of those recombinant viruses themselves or for production of foreign proteins or glycoproteins encoded by them, and hence find application in (glyco) protein production or in providing vector systems for somatic gene therapy or in being used as vaccination agents.
• RNA polymerase I synthesis of recombinant vRNAs in vivo, in antisense, or in sense tandem design
• influenza carrier strain constructed to include flanking ribozyme target sequences in the corresponding viral RNA segment, i.e., coding for the same viral gene as present in the tandem segment distal position, and (c) thereafter selective vRNA inactivation through ribozyme cleavage
• (10) a method for preventing and/or treating influenza which comprises administering a recombinant influenza virus as defined in (1) and (2) above to the mammal to be treated, i.e., a vaccination method utilizing said recombinant virus;
• (11) a method for somatic gene therapy, which method comprises subjecting the organism to be treated with a recombinant influenza virus as defined in (1) and (2) above;
• a method for transfer and expression of foreign genes into cells, and for transfer and expression of RNA molecules into cells comprises infecting the cells with a recombinant influenza virus as defined in (1) and (2) above; (13) use of a recombinant influenza virus as defined in (1) and (2) above for preparing agents for autologous immunotherapy;
• Fig. 1 shows the basepair substitution analysis according to the vRNA 'corkscrew' structure:
• Fig. 2 Vector plasmid pHL1920, the excact sequence of the 3888 bps circular DNA is shown in SEQ ID NO: 20
• Fig. 3 shows the genetic structure and the RNA transcription products of influenza model tandem expression constructs. Heavy lines for the plasmid cDNA constructs refer to double-stranded DNA, while single- stranded RNA molecules are represented by thin lines, and their 5' to 3' directionalities are marked by arrows. Standard modifications at their 5' and 3' ends are indicated by a dot (5' cap structure) and A n (3' poly- adenylation), both are absent in the primary anti-sense transcription product, the viral RNA (vRNA), which is transcribed by cellular RNA polymerase I (RPoI).
• vRNA viral RNA
• RPoI cellular RNA polymerase I
• mRNA Full-length, mRNA,. is synthesized by influenza viral polymerase (virPo), and a partial splice reation results in a functional yield of shorter mRNA 2 molecules. While both of the reporter genes are indicated on the DNA level, together with the positions of splice donor (D) and acceptor (A) signal sequences as well as the promotor (pi) and terminator (ti) elements for RNA polymerase I start and stop, on the RNA level only those genes and splice signals are marked that are actually translated into protein or actively involved in splicing.
• V viral polymerase
• the chloramphenicol-acetyltransferase gene has been inserted in proximal position in pHL3196 and pHL3235, and in distal position in pHL3224 and pHL3236 (see Figs. 5 to 8), while green fluorescent protein (GFP) in each case is located in alternate location.
• All vRNA molecules - and hence, also the cDNA constructs - carry sequence variations at their 3' ends, which together constitute the 1104 promoter-up mutations: G3A, U5C, C8U (nucleotide positions counted from the 3' vRNA end).
• pHL3235 and pHL3236 vRNAs are extended in size by about 1000 nucleotides of untranslated sequence relative to pHL3196 and pHL3226: 2600 instead of
• Fig. 4 shows the CAT assay results for the group of tandem vRNA plasmid constructs as described in the Example.
• the ratio between chloramphenicol (bottom line) and acetylchloramphenicol (upper three lines) in a flash-CAT assay, after the 2 nd (A) and 4 th (B) passage of recombinant viruses carrying the reportergene CAT can be determined from said figure.
• the following constructs were utilized: pHL1844 (control): monocistronic CAT-construct downstream of promoter variant 1104.
• ⁇ HL3196 tandem construct, p-CAT-GFP resulting in a vRNA having a total length of 1530 nucleotides (not “extended"), see also Fig. 5.
• pHL3235 tandem construct, p-CAT-GFP resulting in a vRNA having a total length of 2550 nucleotides ("extended"), see also Fig. 7.
• pHL3224 tandem construct, p-CAT-GFP resulting in a vRNA having a total length of 1700 nucleotides (not “extended"), see also Fig. 6.
• pHL3236 tandem construct, p-CAT-GFP resulting in a vRNA having a total length of 2720 nucleotides ("extended"), see also Fig. 8.
• ⁇ HL2899 ambisense construct, p v -CAT ⁇ -GFP-p c resulting in an RNA having a total length of 1500 nucleotides.
• pHL2960 ambisense construct, p v -CAT-» ⁇ -GFP-p c resulting in an RNA having a total length of 1500 nucleotides.
• the five constructs on the left side were transfected into the cell DNA without the use of "booster” plasmides, the four constructs on the right side were, however, transfected with the "booster” plasmides, which gives a jump-start of the constructs due to recombinant vRNA amplification prior to helper virus injection, equivalent to an advantage of about two passages.
• the "booster” plasmides comprise expression constructs for the nucleoprotein as well as the three subunits of influenza viral polymerase, each downstream of an RNA polymerase II promoter and in an mRNA forming cassette.
• Fig. 5 Vector plasmid pHL3196, the exact sequence of the 4500 bps circular DNA is shown in SEQ ID NO:21.
• Fig. 6 Vector plasmid pHL3224, the exact sequence of the 4721 bps circular DNA is shown in SEQ ID NO:22.
• Fig. 7 Vector plasmid pHL3235, the exact sequence of the 5517 bps circular DNA is shown in SEQ ID NO:23.
• Fig. 8 Vector plasmid pHL3236, the exact sequence of the 5699 bps circular DNA is shown in SEQ ID NO:24.
• influenza virus embraces influenza A virus, influenza B virus and influenza C virus, with influenza A virus being preferred.
• “Bicistronic” refers to a viral RNA segment, vRNA, cRNA or mRNA that includes two independent genes in covalent junction; in a preferred version one of these genes is of viral origin, while the other one codes for a foreign, recombinant gene product.
• Proximal and proximal position refers to the 5' portion of one of the genes in the bicistronic viral mRNA, i.e., ahead (upstream) of the second gene in “distal position”.
• a “mammal” according to the present invention includes humans and animals.
• “Organism” embraces prokaryotic and eukaryotic systems as well as multicellular systems such as vertebrates (including mammals) and invertebrates.
• Infected cells and “infecting cells” according to the present invention also include “abortively infected cells” and “abortively infecting cells”, respectively.
• a preferred influenza virus in a preferred influenza virus according to embodiment (1) at least one of the regular viral RNA segments ,is replaced by a tandem RNA segment which contains one of the standard viral genes in distal position, and a foreign, recombinant gene in proximal position, both in anti-sense orientation, or vice-versa. It is moreover preferred that in the tandem RNA molecule said foreign recombinant gene is covalently bound to one of the viral genes while the original vRNA segment coding for the same gene is deleted from the recombinant virus by specific ribozyme cleavage.
• the foreign gene(s) in tandem covalent junction with the viral gene(s) preferably code for proteins and/or glycoproteins which are secreted from ceils infected with the recombinant virus, such as lymphokines, or code for glycoproteins that are incorporated into the virion as well as the plasma membrane of the infected cell.
• the foreign gene(s) in tandem covalent junction with the viral gene(s) code for proteins or artificial polypeptides designed to support an efficient presentation of inherent epitopes at the surface of infected cells, for stimulation of B cell and/or T cell response.
• proteins or artificial polypeptides constitute for instance a tumor antigen or an artificial oligomeric series of T cell epitopes that have been identified within a polypeptide chain.
• the foreign gene(s) may be suitable for transfer and expression of RNA molecules, including antisense RNAs and ribozymes, into cells.
• RNA molecules including antisense RNAs and ribozymes
• Such recombinant influenza viruses are suitable for sequence specific gene silencing, for example by antisense or RNA interference mechanisms.
• a preferred recombinant virus of the invention is where in the regular viral RNA segments one or both of the standard glycoproteins hemagglutinin and neuraminidase have been exchanged, preferably into fusion glycoproteins consisting of an anchor segment derived from hemagglutinin and an ectodomain obtained from the foreign source, viral or cellular, or in which such recombinant glycoprotein has been inserted as a third molecular species in addition to the remaining standard components.
• a preferred recombinant virus of the invention is where the terminal viral RNA sequences, which are active as promoter signal, have been modified by nucleotide substitution in up to 5 positions, resulting in improved transcription rates (of both the vRNA promoter and in the cRNA promoter as present in the complentary sequence) as well as enhanced replication and/or expression rates relative to the wild-type sequence.
• Said modified terminal viral RNA sequences differ from the wild-type sequence in that in said tandem vRNA segment the 12 nucleotide conserved influenza 3' terminal sequence has been modified by replacement of one to three nucleotides occurring in said sequence at positions 3, 5 and 8 relative to the 3' end by other nucleotides provided that the nucleotides introduced in positions 3 and 8 are forming a base pair (i.e., if the nucleotide position 3 is G, than that in position 8 is C; if the nucleotide in position 3 is C, than that in position 8 is G; etc.).
• the 3' conserved regions of the wild-type influenza virus have the following sequences:
• Influenza B (5')-NN(C/U)GCUUCUGCU-3' Influenza C: (5')-CCUGCUUCUGCU-3'.
• the 13 nucleotide conserved influenza 5'-terminal sequence may be modified by replacement of one or two nucleotides occurring in said sequence as positions 3 and 8 by other nucleotides, again provided that the introduced nucleotides are forming a base pair.
• the 5' conserved regions of the wild-type influenza virus have the following sequences: Influenza A: 5'-AGUAGAAACAAGG Influenza B: 5'-AGUAG(A/U)AACA(A/G)NN Influenza C: 5'-AGCAGUAGCAAG(G/A):
• Preferred influenza viruses of the invention are those wherein in the 3' conserved region the replacements G3A and C8U have been performed, more preferred are those where also the replacement U5C has been performed (the above mutations are annotated relative to the 3' end; such counting from the 3' end is also indicated by a line on top of the digit, e.g., G 3A).
• Another preferred influenza virus mutant comprises the 3'-terminal nucleotide sequence G3C, U5C and C8G (relative to the 3' end) resulting in the following 3' terminal nucleotide sequence (5')-CCUGGUUCUCCU-3 ⁇
• the influenza viruses defined hereinbefore those having a 3'- terminal nucleotide sequence of (5')-CCUGUUUCUACU-3' are most preferred.
• the segment may further have the modifications U3A and A8U in its 5' terminal sequence
• influenza C it may have the modifications C3U and G8A in its 5' terminal sequence.
• the most preferred influenza viruses of the present invention comprise the following general structures: Influenza A (mutant PHL1104 : ntds)..N , N'N , CCUGUUUCuACU-3'
• Influenza A (mutant pHL1920 :
• Influenza A (mutant DHL1948 : 5'-AGUAGAAACAAGGNNNU 5-6 .. (880-2300 ntds)..N'N'N , CCUGGUUCuCCU-3'
• Influenza B 5'-AGUAG(A/U)AACA(A/G)NNNNNU 5 - 6 .. (880-2300 ntds ⁇ .N'N'N'N'N'N' C/U ⁇ UUUCUACU-S'
• N and N' positions undefined, but base-paired relative to each other because of complementarity between the 5' and 3' termini, different among the 8 segments, but constant for each segment throughout all viral isolates;
• both gene products in these constructions is made possible by way of an upstream splice donor and a downstream splice acceptor signal surrounding the proximal coding region of such a quality that splicing does occur in part of the mRNA molecules only, i.e., both mRNAs spliced and unspliced are present in the infected cell.
• the bicistronic segment is connected to a promoter variant of enhanced replication and transcription rates as defined herein before.
• the splice donor and the splice acceptor signals are selected from authentic sequences as present in influenza segments 7 and 8 or other partially effective splice reaction substrates, preferably those of influenza virus WSN segment 7, i.e., 5'-AG ⁇ GTACGTTC-3' (donor) and 5'- GCTGAAAAATGATCTTCTTGAAAATTGCAG ⁇ GC-3' (acceptor) .
• tandem bicistronic mRNA codes for one of the viral genes, such as hemagglutinin, in conjunction with all or part of the viral neuraminidase coding sequence, in antisense orientation, while the authentic neuraminidase vRNA segment is missing in these recombinant viruses.
• an anti-neuraminidase ribozyme sequence is also provided together with the (partial) neuraminidase antisense sequence, in the proximal position of these bicistronic recombinant segments. Recombinant viruses of this character are propagated in culture media with addition of exogenous neuraminidase.
• a functional neuraminidase gene serves as a strong attenuation mechanism resulting in single-step infections of such recombinant viruses only. While a functional neuraminidase gene could be provided through another (wildtype) influenza virus superinfecting the same cell, expression of that gene is very much reduced through antisense RNA interaction and/or destruction of the corresponding vRNA through ribozyme cleavage, designed to interfere with production of infectious progeny even from co-infected cells; as a barrier against reassortment in double infected cells.
• Recombinant viral RNAs coding simultaneously for two genes in tandem in a construct in which one of the viral genes is in covalent junction with a foreign coding sequence are constructed via E. coli plasmid vector DNAs designed for an in vivo transcription of minus-strand vRNAs by cellular RNA polymerase I.
• the gene in plus-strand proximal (upstream) position is surrounded by splice signals of limited activity such that both mRNAs, spliced and unspliced are present in the infected cell.
• Either the foreign gene or the viral gene may be in that upstream position.
• the higher rates of expression will be reserved for the foreign coding sequence, while the lower expression rate of the viral gene is adapted to be approximately in balance with expression of the other viral genes encoded by the regular viral segments.
• the splice signals and the promoter have to be chosen properly (Flick and Hobom, Interaction of influenza virus, polymerase with viral RNA in the 'corkscrew' conformation, J. Gen. Virol. 80, 2565-2572 (1999)).
• the resulting mRNAs shall be spliced inefficiently if the viral gene is in the distal (downstream) position.
• the foreign gene if the foreign gene is in the distal position, splicing to obtain the foreign mRNA shall be achieved efficiently.
• Both designs serve to reach an over-expression of the foreign gene relative to the viral gene, of which the expression shall be in balance with the expression of the other viral genes.
• the promoter variant attached to the bicistronic segment has the function to compensate for the increased gene length by way of an increased replication rate.
• influenza vRNA segments preferably used for construction of bicistronic segments include the neuraminidase (No. 6), hemagglutinin (No. 4) and NS segment (No. 8). In the NS segment the foreign gene may also substitute for the NS1 gene leaving the viral NS2 gene in its place.
• These recombinant viruses can, as an example, be made by the following procedure: A recombinant virus population can be selected by repeated ribozyme-mediated cleavage of helper-virus segments carrying ribozyme cleavage sites that flank the same viral gene in the monocistronic segment as is present in the bicistronic construct (PCT/EPOO/01903).
• a balanced mode of expression can be achieved in choosing the right set of elements: promoter, splice signals plus a limited variation in segment length.
• the construct that gives rise to the balanced, stable expression is then used as a basis for a multiple cDNA transfection procedure in a helper-virus free design according to Neumann et al., Proc. Natl. Acad. Sci. USA, Vol 96, 9345-9350 (March 1999).
• the resulting recombinant influenza virus obtained via single plaques in pure helper-free state is subjected to another series of propagation steps to finally evaluate its properties.
• this design is used for a controlled mode of viral attenuation.
• Attenuation of influenza viruses so far has been achieved in cold-sensitive mutants (Edwards et al., J. Infect. Dis. 169, 68-76(1994)), by deletion of the NS1 gene (partial attenuation, Egorov et al., J. Virol. 72, 6437-6441 (March 1998) and Palese et al., Proc. Natl. Acad. Sci USA, 4309-4314 (April 2000)), or through deletion of the neuraminidase gene (full attenuation, Kawaoka et al., J. Virol. 74, 5206-5212 (June 2000)).
• the latter approach is adapted here using a novel technique for the attenuation, which for the first time is also able to interfere with (chance) superinfection by wild-type viruses.
• a bicistronic cDNA construct is achieved, which instead of a foreign gene is coding either for part of or for the entire viral neuraminidase gene in antisense orientation, with or without being surrounded both by splice donor and acceptor elements.
• a 2 x 50 nucleotide antisense segment complementary to the 5'-terminal neuraminidase sequence has been cloned in flanking positions relative to a ribozyme construct according to the hammerhead design and oriented against a common GUC triplett within the neuraminidase sequence.
• this antisense expression construct has been attached to the hemagglutinin vRNA segment, while another gene or reporter gene is encoded in a second bicistronic vRNA, in conjunction with NS2.
• NA neuraminidase
• the pharmaceutical composition according to embodiment (4) above and the medicament of embodiment (5) above contain the recombinant influenza virus in a pharmaceutically effective amount.
• the pharmaceutical composition and the medicament may contain further pharmaceutically acceptable carrier substances well-known to a person skilled in the art, such as binders, desintegrants, diluents, buffers, preservatives, etc.
• the pharmaceutical composition and medicaments are solid or liquid preparations and are suitable to be administered orally, intravenously or subcutaneously.
• the medicament according to embodiment (5) above is preferably suitable as a medicament against influenza and/or against other infections.
• the recombinant influenza virus may be present in form of inactivated preparations or may be present in form of live recombinant viruses, preferably as attenuated viruses.
• Live recombinant viral vaccines live but attenuated recombinant viral vaccines or inactivated recombinant viral vaccine can be formulated.
• Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity is destroyed without affecting its immunogenicity.
• the recombinant virus may be grown in cell cultures or in embryonated chicken eggs, purified, and inactivated by formaldehyde or ⁇ -propiolactone. The resulting vaccine is usually administered intramuscularly.
• Inactivated viruses may be formulated with suitable adjuvants to enhance the immunological response.
• suitable adjuvants include, but are not limited to, mineral gels, e.g., aluminum hydroxide, surface-active substances such as pluronic polyols, lysolecithin, peptides, oil emulsions, and potentially useful human adjuvants such as BCG.
• vaccine formulations for example the oral, intradermal, intramuscular, intraperitoneal, subcutaneous, or intranasal routes.
• a live recombinant virus vaccine it is preferred to introduce the formulation via the natural route of infection for influenza virus.
• the medicament according to embodiment (5) above is preferably suitable for prophylactic or therapeutic vaccination, or both, against influenza and other infections.
• recombinant viruses can be made for use in vaccines against HIV, hepatitis B virus, hepatitis C virus, herpes viruses, papilloma viruses, to name but a few.
• the recombinant virus contains the genes for surface proteins of the viruses, in another the genes for non-structural or regulatory genes.
• the recombinant viruses may be present in form of inactivated preparations or may be present in form of live recombinant viruses, or as live, but attenuated viruses.
• the recombinant virus In an attenuated virus the recombinant virus would go through a single or at most very few propagation cycle(s) and induce a sufficient level of immune response, but would not cause disease.
• Such viruses lack one of the essential influenza genes or contain mutations to introduce temperature sensitivity.
• the agents of embodiments (6)-(8) of the invention are applicable in ex vivo and in vivo application schemes.
• the RNA molecule to be expressed by means of the agent of the embodiment (8) is of an antisense sequence or double strand sequence (in ambisense bidirectional transcription) relative to a target cellular mRNA molecule.
• the agent is preferably suitable for sequence-specific gene silencing, preferably by antisense RNA or RNA interference mechanisms.
• the method for the production of proteins or glycoproteins is preferably performed in cell culture cells or in fertilized chicken cells in accordance with standard techniques within the general knowledge of a person skilled in the art.
• the proteins or glycoproteins to be expressed are those incorporated into the ambisense construct as defined hereinbefore.
• the methods according to embodiments (9) to (12), (14) and (15) of the invention include the administration of an effective amount to the mammal or the administration of a sufficient infective dose of the recombinant virus to the cell system that is used for ex vivo therapy or for in vitro investigations, whereby the amount and dose will be determined by a person skilled in the respective arts or knowledgeable of the desired treatments.
• the agent of embodiment (14) of the invention is preferably utilized to infect, transfect or transduce patient-derived immune cells.
• the agent is suitable for treatment of cancer or chronic viral infections.
• patient derived immune cells preferably dendritic cells, are ex vivo infected with recombinant influenza viruses expressing, e.g., tumor antigens or viral antigens.
• the transduced cells are then reintroduced into the patient.
• the preferred method for immunotherapy of embodiment (14) of the invention is an autologous immunotherapy, wherein the cells which are ex vivo infected are patient-derived and the transduced cells are reintroduced into the patient.
• the diseases to be treated by this method include cancer and chronic viral infections. For details regarding such treatment see discussion of embodiment (13) above.
• the method for inducing antibodies according to embodiment (15) of the invention is suitable for inducing antibodies to foreign proteins including glycoproteins, following the administration of protein or glycoprotein antigens as part of a recombinant influenza virus in an authentic conformation, whereby the virus is purified by gentle procedures based on hemagglutination, and the gene is expressed at high rates in the infected cells.
• influenza viruses have a wide host range
• recombinant influenza viruses can be used to obtain strong immune responses in, and isolate antibodies from, a wide range of animals, including, but not limited to, fowl, pigs, horses, and mice.
• influenza viruses adapted to the mouse can be used for the infection of mice by several routes including the intranasal route. This results in infection of the pharyngeal mucosal cells and results in an additional type of B cell response (e.g., as recognized in the ratio of IgG to IgA).
• Mice are of particular utility in the induction of immune responses in transgenic mice that have been engineered to express human antibodies. As gentle procedures based on hemadsorption are used to purify influenza viruses, antibodies to antigens in native conformation can be isolated from the infected mammals.
• the preset invention further illustrated by the following, non-limiting Example:
• Model tandem bicistronic expression constructs using reporter genes CAT and GFP Objective: Measurements of relative expression rates for CAT in proximal and distal position, with live observation of GFP fluorescence in alternate position during propagation of recombinant influenza viruses, a) Construction of bicistronic expression plasmid DNAs: Starting out with vector plasmid pHHIO (Hoffmann, Ph.D. Thesis, Univ. Giessen (1997)), i.e.
• an ampicillin resistant plasmid including in between a human rDNA promoter segment and a murine rDNA terminator segment precisely inserted cDNA sequence elements representing the 5' and 3' vRNA sequence of influenza rRNA segment 5, and finally a central multiple cloning site sequence as obtained from plasmid PBSK, both reporter genes have been inserted in a stepwise manner.
• a proximal reading frame i.e. CAT in pHL3196, and GFP in pHL3224, has been added an upstream splice donor sequence element and a downstream splice acceptor element, both inserted as double-strand oligonucleotides, in between particular restriction cleavage sites available in the respective positions.
• the signal sequences used in that pair of plasmids indicated above have been derived from influenza vRNA segment 7, which is known for its partial splice reactions yielding both gene products, Ml and M2, simultaneously.
• a non-transcribed DNA fragment (representing an internal segment " of the influenza PB1 coding region) in a distal position relative to both reading frames, pHL3196 has been converted into pHL3235, and pHL3224 into pHL3236.
• Figs 5-8 and SEQ ID NOs: 21-24 For the resulting plasmid constructs see Figs 5-8 and SEQ ID NOs: 21-24.
• Semi-confluent 293-T cells a human renal creatnoma cell line carrying an artificially integrated tumor virus SV40 T-antigen gene, were DNA- transfected using lipofectamine: 5-10 ⁇ g of DNA mixed with 30 ⁇ l Lipofectamine ® (GIBCO/BRL) were added to 370 ⁇ l of DMEM medium and were incubated with 5xl0 6 to 10 7 cells, washed and maintained serum- free for 5 to 8 hours, before serum was added for another 12 to 15 hours. Finally influenza helper virus FPV Br atisiava was used for infection of the DNA- transfected cells.
• lipofectamine 5-10 ⁇ g of DNA mixed with 30 ⁇ l Lipofectamine ® (GIBCO/BRL) were added to 370 ⁇ l of DMEM medium and were incubated with 5xl0 6 to 10 7 cells, washed and maintained serum- free for 5 to 8 hours, before serum was added for another 12 to 15 hours.
• influenza helper virus FPV Br atisiava was
• the supernatant containing a mixture of helper viruses and recombinant viruses was collected for further propagation after 8 to 12 hours of infection, while the sedimented cells were used for preparation of a cell lysate, fractions of which were inserted in the CAT assay procedure.
• Viral propagation was achieved by infection of MDCK cells (Madin-Darby canine kidney cell line) again in semi-confluent state (5xl0 6 to 10 7 cells per plate), generally using 1ml of the previous supernatant for infection. Serial propagations were done in the same way, with preparation of cell lysates for CAT assays at the end of each step. Infected cells were also used for observation of GFP fluorescence.
• Bacterial chloramphenicol-acetyltransferase is accumulated in eukaryotic cells without degradation and can be used for representative gene expression measurements.
• the substrate used here is fluorescent boron-dipyrromethane-chloramphenicol diflouride (FLASH CAT-KIT ® ; Stratagene). 50 ⁇ l of cell lysate or reduced/diluted samples thereof were used for incubation with 7.5 ⁇ l of fluorescent substrate and 10 ⁇ l acetyl- CoA (4mM) co-substrate in 19 mM Tris/HCI, pH: 7.5 at 37°C for 3 hours.
• reaction products 1ml of ethylacetate ins added, the mixture is vortexed, and separated by centrifugation. After solvent evaporation and dissolution again in 20ml ethylacetate, the reaction products are separated on a silica thin-layer chramatography plate using chloroform/methanol 87: 13% (vol.) and the results are documented by photography under UV light.
• CAT in proximal or in distal position of this pair of recombinant plasmids is expressed about equally (Fig.4), and the same is true for GFP (not shown).
• the expression rates are increasing during the initial steps of viral propagation and stay about constant afterwards during further steps of recombinant viral passages, different from expression rates in ambisense bicistronic constructs (pHL2899 and pHL2960) (Fig. 4B).
• Co- transfection of booster plasmids in the initial 293-T cells increase the yields of recombinant viruses within the progeny population, which are maintained during consecutive steps of propagation. Addition of 1000 nucleotides of untranslated vRNA sequence will not reduce the expression rates substantially (pHL3235 versus pHL3196, and pHL3236 versus pHL3224).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Virology (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Microbiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• General Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Biophysics (AREA)
• Pulmonology (AREA)
• Mycology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Physics & Mathematics (AREA)
• Communicable Diseases (AREA)
• Plant Pathology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=8169305

Family Applications (2)

Family Applications Before (1)

Country Status (7)

Families Citing this family (4)

Family Cites Families (2)

• 2000
  • 2000-07-20 EP EP00115626A patent/EP1174514A1/de not_active Withdrawn
• 2001
  • 2001-07-13 CA CA002418333A patent/CA2418333A1/en not_active Abandoned
  • 2001-07-13 NZ NZ523895A patent/NZ523895A/en unknown
  • 2001-07-13 EP EP01967171A patent/EP1301616A2/de not_active Withdrawn
  • 2001-07-13 AU AU2001287615A patent/AU2001287615A1/en not_active Abandoned
  • 2001-07-13 JP JP2002513917A patent/JP2004508814A/ja active Pending
  • 2001-07-13 WO PCT/EP2001/008124 patent/WO2002008434A2/en active IP Right Grant
• 2003
  • 2003-01-29 ZA ZA200300784A patent/ZA200300784B/xx unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events